Dong-Wan Kim; Hoon-Gu Kim; Joo-Hang Kim; Keunchil Park; Hoon-Kyo Kim; Joung Soon Jang; Bong-Seog Kim; Jin-Hyoung Kang; Kyung Hee Lee; Sang-We Kim; Hun Mo Ryoo; Jin-Soo Kim; Ki Hyeong Lee; Jung Hye Kwon; Jin-Hyuk Choi; Sang Won Shin; Seokyung Hahn; Dae Seog Heo

doi:10.4143/crt.2018.019

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(1); 2019 > Article

Original Article Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer: Dong-Wan Kim, MD, PhD¹, Hoon-Gu Kim, MD, PhD^2,a, Joo-Hang Kim, MD, PhD^3,b, Keunchil Park, MD, PhD⁴, Hoon-Kyo Kim, MD, PhD⁵, Joung Soon Jang, MD, PhD⁶, Bong-Seog Kim, MD, PhD⁷, Jin-Hyoung Kang, MD, PhD⁸, Kyung Hee Lee, MD, PhD⁹, Sang-We Kim, MD, PhD¹⁰, Hun Mo Ryoo, MD, PhD¹¹, Jin-Soo Kim, MD, PhD¹², Ki Hyeong Lee, MD, PhD¹³, Jung Hye Kwon, MD, PhD¹⁴, Jin-Hyuk Choi, MD, PhD¹⁵, Sang Won Shin, MD, PhD¹⁶, Seokyung Hahn, MD, PhD¹⁷, Dae Seog Heo, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(1):119-127.
DOI: https://doi.org/10.4143/crt.2018.019
Published online: March 12, 2018

¹Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

²Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

³Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

⁴Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea

⁵Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea

⁶Division of Hematology/Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

⁷Division of Hemato-Oncology, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Korea

⁸Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Seoul, Korea

⁹Department of Hematology-Oncology, Yeungnam University Medical Center, Daegu, Korea

¹⁰Division of Oncology, Department of Internal Medicine, Asan Medical Center, Seoul, Korea

¹¹Department of Internal Medicine, Daegu Catholic University Hospital, Daegu, Korea

¹²Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea

¹³Division of Medical Oncology, Chungbuk National University Hospital, Chungju, Korea

¹⁴Division of Hematology-Oncology, Department of Internal Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea

¹⁵Department of Hematology-Oncology, Ajou University Hospital, Suwon, Korea

¹⁶Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea

¹⁷Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea

Correspondence: Dae Seog Heo MD, PhD Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: 82-2-2072-2857 Fax: 82-2-764-2199 E-mail: heo1013@snu.ac.kr

aGyeongsang National University College of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Korea
bCHA Bundang Medical Center, CHA University, Seongnam, Korea
*This study was presented in part at the 2013 World Conference on Lung Cancer, Sydney, Australia, October 27-30, 2013.

• Received: January 5, 2018 • Accepted: March 8, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13,483 Views
532 Download
32 Web of Science
26 Crossref
33 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC).
Materials and Methods
Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m² intravenously on days 1 and 8+cisplatin 70 mg/m² intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m² intravenously on days 1, 2, 3+cisplatin 70 mg/m² intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival.
Results
A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP.
Conclusion
The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.
Key words: Etoposide, Irinotecan, Cisplatin, Small cell lung carcinoma, Korean

Introduction

Lung cancer is one of the leading causes of the cancer-related deaths [1,2]. Approximately 15% of new cases of lung cancer are diagnosed with small cell lung cancer (SCLC) [3]. Most patients with SCLC present with hematogenous metastases, and approximately two-thirds of the patients present with extensive disease. Despite the substantial initial sensitivity of SCLC to chemotherapy, a majority of patients with extensive-disease (ED) SCLC eventually die within 1 year of initial diagnosis as a result of the relapse. Thus, both new regimens and alternative doses and schedules are considered to be treatment options for patients with ED SCLC.

The platinum-based chemotherapy consisting of etoposide and cisplatin (EP) has been the standard therapy for ED-SCLC for decades [4-7]. The response rates typically achieved with EP regimen ranged from 60% to 80% with median overall survival (OS) of 8 to 10 months. Preliminary studies with irinotecan hydrochloride, a topoisomerase I inhibitor, revealed the promising outcome against SCLC and the subsequent phase II study with irinotecan and cisplatin reported a complete response rate of 29% and an overall rate of 86% in patients with ED SCLC [8,9]. Based on these initial reports, the Japanese Cooperative Oncology Group (JCOG) conducted a phase III study to compare the efficacy and toxicity of irinotecan plus cisplatin (IP) versus EP as the firstline of chemotherapy for ED-SCLC [10,11]. Median OS and 1-year survival rate were significantly higher with IP than with EP (median survival for IP vs. EP, 12.8 vs. 9.4 months, and 1-year survival rate, 58.4% vs. 37.7%). The severe toxicity in the IP arm was grade 3/4 diarrhea whereas the severe myelosuppression was observed more frequently in the EP arm.

Despite this positive role of IP for ED SCLC, two subsequent large-scale phase III trials failed to confirm the superior outcome of IP over EP in the United States, Australia, and Canada [12-14]. The cause of inconsistent result for IP regimen between Japanese and Western populations has not been elucidated yet. One possible cause is the pharmacogenetic difference of irinotecan between Asian and Western population. Based on the rationale that Korean and Japanese population might share substantial degree of pharmacogenetic profile compared to Western population, we hypothesized that the efficacy of IP in Korean patients with ED SCLC might be superior to that of EP. To test this hypothesis, we conducted the phase III trial to evaluate the efficacy and safety of IP versus EP regimen for chemotherapy naïve patients with ED SCLC in Korea.

Materials and Methods

1. Study population

We conducted a randomized, multi-center, phase III trial to compare the efficacy and safety of IP and EP for chemotherapy naïve patients with ED SCLC (ClinicalTrials.gov Identifier: NCT00-349492).

Eligible criteria were as follows: histologically or cytologically confirmed SCLC; extensive-stage disease (defined as presence of either distant metastasis, contralateral hilar lymph node involvement, or cytologically proven malignant pleural effusion); chemotherapy naïve; Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2; age ≥ 18 years; measurable lesions on computed tomography or magnetic resonance imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.0; adequate function of bone marrow (absolute neutrophils count ≥ 1,500/mm³, white blood cell ≥ 4,000/mm³, and platelet count ≥ 100,000/mm³, hemoglobin ≥ 9.0 g/dL), liver (bilirubin level ≤ 1.5× the upper limit of normal [ULN], and aminotransferase and alanine aminotransferase ≤ 2.5×ULN or ≤ 5×ULN if liver metastases were present), and kidney (creatinine level ≤ 1.5×ULN). Patients with known brain metastases were eligible if they were asymptomatic or neurologically stable without steroids after surgery or radiotherapy.

Patients were excluded if they had another malignancy except cured basal cell carcinoma or cured uterine cervical carcinomas in situ within 5 years. The patients with the following conditions were also excluded; had a history of significant cardiovascular disease, serious lung disease, metabolic disease, and serious active infection, had impaired mental status, had enrolled in other study within 30 days, and if they were pregnant and breast-feeding.

2. Treatment and evaluation

Patients were randomly assigned to receive either IP or EPand were stratified by ECOG PS (0, 1 vs. 2) and the treating institutes. The IP regimen consisted of irinotecan 65 mg/m² intravenously on days 1 and 8 and cisplatin 70 mg/m² intravenously on day 1 every 3 weeks. The EP regimen consisted of etoposide 100 mg/m² intravenously on days 1, 2, 3 and cisplatin 70 mg/m² intravenously on day 1 every 3 weeks. Treatment in each arm was repeated for a maximum of six cycles. Primary prophylactic use of granulocyte-colony stimulating factor (G-CSF) was not allowed before the first cycle of treatment, but secondary prophylactic use of G-CSF after neutropenia was allowed. Prophylactic cranial irradiation after completion of study treatment and crossover treatment after disease progression were allowed based upon investigator’s discretion.

Toxicity was evaluated after each cycle according to National Cancer Institute Common Toxicity Criteria ver. 3.0 [15]. Patients were evaluated for response according to RECIST ver. 1.0 guideline [16].

3. Statistical methods

The primary objective of this study was to compare the OS in patients with extensive stage small-cell lung cancer treated with EP (standard arm) with that in comparable patients treated with the IP (experimental). IP would be judged superior to the standard if the true increase in median OS was 3.0 months. We used Freedman’s sample size formula for log-rank statistic assuming that the hazard ratio (HR) is constant throughout the trial [17]. A total of 333 events were required to demonstrate a significant superiority of OS with an α of 5% and a power of 80% at final analysis, using a one-sided stratified log-rank test. Assuming that the expected survival rate will be 5.2% at 18 months in the standard arm, a total of 362 patients were calculated. Planned interim analysis was conducted at the time of 166 events (50% of target events) occurred. α1=0.0055 and α2=0.0482 were used by O’Brien Flemming method. OS and progression-free survival (PFS) were calculated using the Kaplan-Meier method and log-rank test was employed to compare survival rates. HR was presented together with the 90% two-sided confidence interval. OS was calculated from the day of start of treatment until death by any cause; surviving patients were censored at the last date of follow-up. PFS was calculated from the day of treatment until disease progression or death from any cause. Efficacy was analyzed on intention-to-treat population. Exploratory subgroup analysis was planned to be conducted by considering factors such as sex, age, and ECOG status.

4. Ethical statement

The study was approved by the Institutional Review Boards of participating institutions (Seoul National University Hospital, Seoul; Gyeongsang National University Hospital, Jinju; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul; Samsung Medical Center, Seoul; St. Vincent’s Hospital, The Catholic University of Korea, Suwon; Chung-Ang University College of Medicine, Seoul; Veterans Health Service Medical Center, Seoul; Seoul St. Mary’s Hospital, Seoul; Yeungnam University Medical Center, Daegu; Asan Medical Center, Seoul; Daegu Catholic University Hospital, Daegu; SMG-SNU Boramae Medical Center, Seoul; Chungbuk National University Hospital, Chungju; Hallym University College of Medicine Kangdong Sacred Heart Hospital, Seoul; Ajou University Hospital, Suwon; Korea University Anam Hospital, Seoul; Soon Chun Hyang University Bucheon Hospital, Bucheon) and was conducted in compliance with Declaration of Helsinki. Written informed consent was obtained from all patients before enrollment.

Results

1. Patients and treatment

The characteristics of the patients are listed in Table 1. Most patients (> 85%) were male. The median age for IP and EP arm was 66 years (range, 47 to 80 years) and 65 years (range, 36 to 81 years), respectively. More than 80% of patients had an ECOG PS of 0 or 1. More than 60% of patients had metastases to the bone and brain metastases were detected in about 25% of patients. Baseline characteristics were well balanced between arms.

From June 2006 to November 2011, 362 patients were enrolled in this study at 19 sites with 173 patients randomly assigned to receive IP and 189 patients randomly assigned to receive EP (S1 Fig.). All patients who received at least one cycle of study treatment were assessable for the efficacy and toxicity analyses. Six and two patients in IP and EP arm were given no chemotherapy because they didn’t meet the enrollment criteria. These patients were excluded from the toxicity analysis. For the remaining 167 patients in the IP arm, the mean dose intensities of irinotecan and cisplatin were 92.6% and 95.4% (irinotecan, 120.4 mg/m²/wk of 130 mg/m²/wk and cisplatin, 66.8 mg/m²/wk of 70 mg/m²/wk) of the planned doses, respectively. For the remaining 187 patients in the EP arm, the mean dose intensities of EP were 96.1% and 97% (etoposide, 288.5 mg/m²/wk of 300 mg/m²/wk and cisplatin, 67.9 mg/m²/wk of 70 mg/m²/wk) of the planned doses, respectively. There were no significant differences between two arms in treatment delivery.

The number of the patients who completed the study was 97 (56%) and 98 (51%) in the IP and EP arm, respectively. The most common reason for not completing study was due to progressive disease, treatment-related complications, unacceptable toxicity, and deaths. The median number of cycles of chemotherapy administered was 6 in each arm; more than 96 % of patients on the IP and EP arm received at least one study treatment. The duration of follow-up time was 12.5 months in the IP arm and 11.4 months in the EP arm.

2. Survival and tumor response

There was no significant difference between two arms in OS (median OS, 10.9 vs. 10.3 months; p=0.120) and PFS (median PFS, 6.5 vs. 5.8 months; p=0.115), The Kaplan-Meier curves of OS and PFS of the assessable patients are shown in Figs. 1 and 2. The 1-year and 2-year OS rates between two arms were also similar. This result indicates that there is no significant difference in survival rate between two arms. In the pre-defined exploratory subgroup analysis (Fig. 3), however, HRs for OS seemed to favor the IP treatment arm in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and ECOG performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. There was a significant prolongation of survival in the IP over EP regimen within these patient groups.

Tumor response data are shown in Table 2. In the IP and EP arms, respectively, 24 (13.9%) and 51 (30%) experienced stable disease, and 2.3% and 9.5% experienced progressive disease. There were two complete responses (1.1%) and 106 partial responses (61.3%) in the IP arm while there were three complete responses (1.6%) and 88 partial responses (46.6%) in the EP arm. There was a significant difference in objective response rate between IP and EP arms (p=0.006); Objective response rate in the IP arm was 62.4% and 48.4% in the EP arm.

3. Toxicity

Grade ≥ 3 adverse events which occurred in more than 2% of subjects are summarized in Table 3. The most common toxicity with grade ≥ 3 or more was neutropenia; 104 patients (62.3%) and 134 patients (71.7%) experienced grade ≥ 3 neutropenia in the IP and EP arm, respectively. Significantly higher rates of grade ≥ 3 anemia, nausea, and diarrhea occurred in the IP arm compared with the EP arm. There were nine and 10 treatment-related deaths in the IP and EP arm, respectively. Toxicities resulting in discontinuation of study treatment occurred in 17 subjects in the IP arm and 22 in the EP arm.

4. Systemic treatments after progression

Systemic treatments after progression were summarized in Table 4. The proportion of patients who received additional treatment was similar between two arms. Among the patients who received the post-progression systemic treatment, 48.6% of patients in the IP arm received subsequent treatment containing etoposide and 34.4% of those in the EP arm received subsequent treatment containing irinotecan.

Discussion

Results from our study showed no significant difference in the OS in the IP arm, as shown by the median survival time of 10.9 and 10.3 months in the IP and EP arm, respectively. Our results are summarized in Table 5 together with those from other similar studies in the literature. However, the pre-defined exploratory subgroup analysis demonstrated significant benefit of IP over EP in male, < 65 years old, and ECOG PS 0/1 patient groups, indicating that IP regimen might be favorable for these particular groups. There was some imbalance noted in the gender distribution between two treatment groups, with a greater proportion of male in the EP arm by 7% (p=0.038). However, such imbalance dose not influence the overall non-significant treatment difference after adjustment (p=0.121). The objective response rate from our study was also significantly higher in IP arm than EP arm. As in agreement with previous studies, grade 3/4 neutropenia was most frequent in both arms but not significantly different between two arms. However, severe toxicities such as grade 3/4 anemia, nausea, and diarrhea were significantly higher in the IP arm than in the EP arm.

Although there has been the controversy regarding the superiority of IP regimen for ED SCLC, our study suggests that IP regimen might not be superior to EP regimen, the current standard chemotherapy for ED SCLC patients. Several factors such as treated doses and schedules of regimens, patient characteristics, post-study treatment might be responsible for the divergent result between trials. Much attention, however, has been paid to the distinct pharmacogenetics existing between different ethnic populations [18-20]. It is well established that the single-nucleotide polymorphisms (SNPs) of genes involved in the drug disposition vary among ethnic populations. Lara et al. [12] reported that certain SNPs such as ABCB1 (C3435T)T/T and UGT1A1 (G-3156A)A/A seemed to be associated with specific toxicities including diarrhea and neutropenia, but they failed to detect any other genotypes correlated with the treatment efficacy. Intriguingly, however, Han et al. [21] found that ABCC224TT and 3972TT genotypes were associated with higher response rates and longer PFS in Korean patients with advanced non-SCLC. Thus, further ongoing research on the pharmacogenetics is eagerly awaited to further explain the inter-individual and inter-ethnic variability in efficacy and toxicity of chemotherapy. In addition to the role of pharmacogenetics, other genetic alterations might serve as important predictors for response and toxicity to irinotecan. For example, the expression profiling analysis using irinotecan-sensitive and resistant SCLC cell lines might facilitate the identification of novel genes involved in various responses to chemotherapy regimen.

It was of note that, according to our subgroup analysis, IP might be a beneficial treatment option for patient groups with a good performance status. This implies that irinotecan/cisplatin combination might be useful for treating patients with limited-disease (LD) SCLC. Indeed, IP has been tested in randomized phase II trials in patients with LD SCLC. Sohn et al. [22] reported that IP with early concurrent radiotherapy was effective and tolerable in untreated LD-SCLC. Another phase II study of IP induction followed by concurrent twice-daily thoracic radiotherapy with EP chemotherapy for LD SCLC also showed the encouraging results [23]. However, the subsequent phase III trial comparing EP versus IP in patients with LD SCLC treated with EP plus concurrent accelerated hyperfractionated thoracic radiotherapy did not show the improved outcome from IP compared with EP regimen in LD SCLC [24]. Thus, further study is needed to validate IP regimen before recommended as the standard chemotherapy for LD SCLC.

Although the confounding effects of crossover treatment could be a limiting factor to be considered in our study, this study shows that the irinotecan/cisplatin combination as the first-line chemotherapy is not superior to etoposide/cisplatin combination. Furthermore, the toxicity profile of IP was rather unfavorable to EP overall. Therefore, IP might be an alternative treatment option for patients who experience the recurrence after receiving the EP-based first line of chemotherapy.

In conclusion, the IP arm did not show the superior efficacy compared with the EP arm in patients with ED SCLC in Korean patients. Grade 3/4 toxicity was more common in IP arm than in EP arm. However, IP chemotherapy might be beneficial comparing with EP chemotherapy in male, < 65 years old, and ECOG PS 0/1 patient subgroups, indicating that IP regimen might be favorable for these particular groups.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2018-019-suppl.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

We thank the participating patients and their families, all study co-investigators, and research coordinators. We also thank Ms. Soohee Kang (Medical Research Collaboration Center, Seoul National University Hospital, Seoul, Republic of Korea) for the support in statistical analyses. Medical writing assistance was provided by Seonah Ha Ph.D. This work was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A040151).

Fig. 1.

Kaplan-Meier curve of overall survival. IP, irinotecan/cisplatin; EP, etoposide/cisplatin; HR, hazard ratio; CI, confidence interval.

Fig. 2.

Kaplan-Meier curve of progression-free survival. IP, irinotecan/cisplatin; EP, etoposide/cisplatin; HR, hazard ratio; CI, confidence interval.

Fig. 3.

Standard forest plot of the hazard ratio for overall survival according to the pre-defined subgroups. HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IP, irinotecan/cisplatin; EP, etoposide/cisplatin.

Table 1.

Baseline characteristics

Characteristic	Irinotecan plus cisplatin (n=173)	Etoposide plus cisplatin(n=189)	p-value
Age, median (range, yr)	66 (47-80)	65 (36-81)	0.128^a)
Sex
Male	151 (87.2)	177 (93.6)	0.038^b)
Female	22 (12.7)	12 (63.5)
ECOG PS
0	16 (9.2)	19 (10.0)	0.930^b)
1	132 (76.3)	141 (74.6)
2	25 (14.4)	29 (15.3)
Bone metastasis
Absent	61 (35.2)	71 (37.6)	0.690^b)
Present	106 (61.2)	113 (59.8)
Not evaluated	6 (3.5)	5 (2.6)
Brain metastasis
Absent	70 (40.4)	75 (39.7)	0.978^b)
Present	47 (27.1)	50 (26.4)
Not evaluated	56 (32.3)	64 (33.9)
Palliative RT
No	161 (93.0)	174 (92.0)	0.717^b)
Yes	12 (6.9)	15 (7.9)

Values are presented as number (%) unless otherwise indicated. ECOG PS, Eastern Cooperative Oncology Group performance status; RT, radiation therapy.

^a) Wilcoxon rank sum test,

^b) Chi-square test.

Table 2.

Best overall response

Confirmed best response	Irinotecan plus cisplatin (n=173)	Etoposide plus cisplatin (n=189)	p-value
CR	2 (1.2)	3 (1.6)	-
PR	106 (61.3)	88 (46.6)	-
Stable disease	24 (13.9)	51 (27.0)	-
Progressive disease	4 (2.3)	18 (9.5)	-
Not evaluated	37 (21.4)	29 (15.3)	-
Objective response rate (CR+PR) (%)	62.4	48.2	0.006^a)

Values are presented as number (%) unless otherwise indicated. CR, complete response; PR, partial response.

^a) Chi-square test.

Table 3.

Grade ≥ 3 adverse events in more than 2% of subjects

Adverse event	Irinotecan plus cisplatin (n=167)	Etoposide plus cisplatin (n=189)	p-value^a)
Anemia	45 (27.0)	33 (17.5)	0.035
Neutropenia	104 (62.3)	134 (71.0)	0.060
Thrombocytopenia	21 (12.6)	25 (13.2)	0.824
Neutropenic fever	31 (18.6)	33 (17.5)	0.823
Infection	34 (20.4)	33 (17.5)	0.515
Nausea	7 (4.2)	1 (0.5)	0.028
Vomiting	5 (3.0)	3 (1.6)	0.483
Diarrhea	17 (10.2)	5 (3.0)	0.003
AST elevation	2 (1.2)	8 (4.2)	0.110
ALT elevation	3 (1.8)	5 (2.6)	0.727

Values are presented as number (%).

^a) Chi-square test.

Table 4.

Systemic treatments after progression

Treatment	Irinotecan plus cisplatin (n=173)	Etoposide plus cisplatin (n=189)
No systemic treatment	72 (41.6)	73 (38.6)
Etoposide containing regimen	84 (48.6)	9 (4.8)
Irinotecan containing regimen	10 (5.8)	65 (34.4)
Cyclophosphamide+doxorubicin+vincristine	30 (17.3)	26 (13.8)
Topotecan or belotecan	15 (8.7)	39 (20.6)
Paclitaxel	8 (4.6)	11 (5.8)
Ifosfamide	6 (3.5)	5 (2.6)
Others	12 (6.9)	11 (5.8)

Values are presented as number (%).

Table 5.

Comparison of relevant studies of irinotecan-based chemotherapy in patients with ED SCLC

	Present study	Noda et al. [11]	Lara et al. [12]	Hanna et al. [13]
Regimen	Irinotecan 65 mg/m² D 1,8	Irinotecan 60 mg/m² D 1,8,15	Irinotecan 60 mg/m² D 1,8,15	Irinotecan 65 mg/m² D 1,8
	Cisplatin 70 mg/m² D 1	Cisplatin 60 mg/m² D 1	Cisplatin 60 mg/m² D 1	Cisplatin 30 mg/m² D 1,8
	every 3 wk	every 4 wk	every 4 wk	every 3 wk
No. of patients	362	154	651	331
Median OS (mo)	10.9	12.8	9.9	9.3
Median PFS (mo)	6.5	6.9	5.8	4.1
Response rate (%)	62.4	65.0	60.0	48.0
Grade 3/4 neutropenia (%)	62.3	65.3	34.0	36.2
Grade 3/4 diarrhea (%)	10.2	16.0	19.0	21.3

ED, extensive-disease; SCLC, small-cell lung cancer; D, day; OS, overall survival; PFS, progression-free survival.

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. Article PubMed
2. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49:292–305. Article PubMed PMC PDF
3. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–67. Article PubMed
4. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–91. Article PubMed
5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: small cell lung cancer (version 1) [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2015. [cited 2018 Mar 8]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
6. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi99–105. Article PubMed PDF
7. Lebeau B, Chastang C, Allard P, Migueres J, Boita F, Fichet D. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group. Eur Respir J. 1992;5:286–90. Article PubMed
8. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–9. Article PubMed
9. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol. 1998;16:1068–74. Article PubMed
10. Negoro S, Noda K, Nishiwaki Y, Kawahara M, Tamura T, Sugiura T, et al. A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511). Lung Cancer. 2000;29(Suppl 1):S30.Article
11. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91. Article PubMed
12. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–5. Article PubMed PMC
13. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43. Article PubMed
14. Lara PN Jr, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, et al. Common arm comparative outcomes analysis of phase 3 trials of cisplatin+irinotecan versus cisplatin+etoposide in extensive stage small cell lung cancer: final patientlevel results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010;116:5710–5. Article PubMed PMC
15. Common Toxicity Criteria Manual, Common Toxicity Criteria, version 3 [Internet]. Rockville, MD: National Cancer Institute; 2006. [cited 2018 Mar 8]. Available from: http://ctep.cancer.gov/reporting/ctc.html
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. Article PubMed PDF
17. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1:121–9. Article PubMed
18. Shimoyama S. Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events. World J Gastrointest Surg. 2010;2:14–21. Article PubMed PMC
19. de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res. 2004;10:5889–94. Article PubMed
20. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res. 2008;14:1788–96. Article PubMed
21. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007;110:138–47. Article PubMed
22. Sohn JH, Moon YW, Lee CG, Kim GE, Chung KY, Chang J, et al. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. Cancer. 2007;109:1845–950. Article PubMed
23. Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol. 2005;23:3488–94. Article PubMed
24. Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014;15:106–13. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

A Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy
David J. Stewart, Katherine Cole, Stephanie Brule
Current Oncology.2025; 32(5): 258. CrossRef
Treatment of small cell lung cancer; advances and future prospects
Seiji Niho
Respiratory Investigation.2025; 63(4): 680. CrossRef
Factors associated with posttraumatic stress and anxiety among the parents of babies admitted to neonatal care: a systematic review
Reem Malouf, Sian Harrison, Victoria Pilkington, Charles Opondo, Chris Gale, Alan Stein, Linda S. Franck, Fiona Alderdice
BMC Pregnancy and Childbirth.2024;[Epub] CrossRef
Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
Hassan Abdelilah Tafenzi, Farah Choulli, Edwin Kelly Haag, Anass Baladi, Ismail Essaadi, Rhizlane Belbaraka
Translational Oncology.2024; 47: 102015. CrossRef
Clinical Benefits of new Systemic Therapy for Small‐Cell Lung Cancer Over Two Decades: A Cross‐Sectional Study
Yuejing Chen, Honghong Liu, Shaohua Bai, Xuejiao Han, Fei Jin, Bo Cui
The Clinical Respiratory Journal.2024;[Epub] CrossRef
Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
Cancers.2024; 16(22): 3802. CrossRef
Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies
Ying Liu, Lin Wu, Dingzhi Huang, Qiming Wang, Chen Yang, Li Zhou, Shuguang Sun, Xiaomei Jiang, Ying Cheng
Cancer Treatment and Research Communications.2024; 42: 100869. CrossRef
Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
Guo Lin, Zhuoran Yao, Kai Kang, Hui Wang, Ren Luo, You Lu
Cancer Medicine.2023; 12(9): 10230. CrossRef
Therapeutic strategy analysis of patients with advanced stage high‐grade neuroendocrine cervical cancer: A real‐world multicenter study
Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu
International Journal of Gynecology & Obstetrics.2022; 158(3): 722. CrossRef
Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer
Christine M. Cramer‐van der Welle, Franz M. N. H. Schramel, Bas J. M. Peters, John W. G. van Putten, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde
Pharmacoepidemiology and Drug Safety.2021; 30(4): 445. CrossRef
Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
Jung Soo Lee, Seoree Kim, Soo-Yoon Sung, Yeo Hyung Kim, Hyun Woo Lee, Ji Hyung Hong, Yoon Ho Ko
Frontiers in Oncology.2021;[Epub] CrossRef
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
Current Oncology.2021; 28(2): 1094. CrossRef
Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee, Yoon Ho Ko
BMC Cancer.2021;[Epub] CrossRef
Clinical significance of the cachexia index in patients with small cell lung cancer
Se-Il Go, Mi Jung Park, Gyeong-Won Lee
BMC Cancer.2021;[Epub] CrossRef
Sevens Cases of Neuroendocrine Carcinoma of the Nasal and Paranasal Sinuses
Ichiro Sekine, Kan Kishibe, Miki Takahara, Hiroaki Katada, Tatsuya Hayashi, Yasuaki Harabuchi
Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(2): 169. CrossRef
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
Millie Das, Sukhmani K. Padda, Jared Weiss, Taofeek K. Owonikoko
Advances in Therapy.2021; 38(11): 5431. CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef
Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial
Gyeong‐Won Lee, Se‐Il Go, Dong‐Wan Kim, Hoon‐Gu Kim, Joo‐Hang Kim, Ho Jung An, Joung Soon Jang, Bong‐Seog Kim, Seokyung Hahn, Dae Seog Heo
Thoracic Cancer.2020; 11(1): 62. CrossRef
IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
Mi-Sook Lee, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, Yoon-La Choi
Molecular Therapy - Oncolytics.2020; 16: 188. CrossRef
Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
Panpan Zhang, Jie Li, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Zhi Peng, Lin Shen, Ming Lu
Cancer.2020; 126(S9): 2086. CrossRef
Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
Hao Chen, Nobuyuki Horita, Kentaro Ito, Hideyuki Nagakura, Yu Hara, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen

Feiwen Liu, Shaozhang Zhou, Liping Tan, Huiqin Jiang, Yucong Huang
Cancer Management and Research.2020; Volume 12: 10341. CrossRef
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
Ting Zhou, Zhonghan Zhang, Fan Luo, Yuanyuan Zhao, Xue Hou, Tingting Liu, Kai Wang, Hongyun Zhao, Yan Huang, Li Zhang
JAMA Network Open.2020; 3(10): e2015748. CrossRef
Thérapie ciblée et immunothérapie du cancer bronchique à petites cellules
J.-L. Pujol, C. Goze, C. Pujol, B. Roch
Revue des Maladies Respiratoires Actualités.2019; 11(3): 315. CrossRef
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
Fei Xu, Xiaoli Ren, Yuan Chen, Qianxia Li, Ruichao Li, Yu Chen, Shu Xia
BMC Cancer.2018;[Epub] CrossRef
Traitement médical du cancer bronchique à petites cellules : peut-on sortir de l’aire du cisplatine–étoposide ?
Jean-Louis Pujol, Benoît Roch, Camille N. Pujol, Catherine Goze
Bulletin du Cancer.2018;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

Cancer Res Treat. 2019;51(1):119-127. Published online March 12, 2018

DOI: https://doi.org/10.4143/crt.2018.019

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

Fig. 1. Kaplan-Meier curve of overall survival. IP, irinotecan/cisplatin; EP, etoposide/cisplatin; HR, hazard ratio; CI, confidence interval.

Fig. 2. Kaplan-Meier curve of progression-free survival. IP, irinotecan/cisplatin; EP, etoposide/cisplatin; HR, hazard ratio; CI, confidence interval.

Fig. 3. Standard forest plot of the hazard ratio for overall survival according to the pre-defined subgroups. HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IP, irinotecan/cisplatin; EP, etoposide/cisplatin.

Fig. 1.

Fig. 2.

Fig. 3.

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

Characteristic	Irinotecan plus cisplatin (n=173)	Etoposide plus cisplatin(n=189)	p-value
Age, median (range, yr)	66 (47-80)	65 (36-81)	0.128^a)
Sex
Male	151 (87.2)	177 (93.6)	0.038^b)
Female	22 (12.7)	12 (63.5)
ECOG PS
0	16 (9.2)	19 (10.0)	0.930^b)
1	132 (76.3)	141 (74.6)
2	25 (14.4)	29 (15.3)
Bone metastasis
Absent	61 (35.2)	71 (37.6)	0.690^b)
Present	106 (61.2)	113 (59.8)
Not evaluated	6 (3.5)	5 (2.6)
Brain metastasis
Absent	70 (40.4)	75 (39.7)	0.978^b)
Present	47 (27.1)	50 (26.4)
Not evaluated	56 (32.3)	64 (33.9)
Palliative RT
No	161 (93.0)	174 (92.0)	0.717^b)
Yes	12 (6.9)	15 (7.9)

Confirmed best response	Irinotecan plus cisplatin (n=173)	Etoposide plus cisplatin (n=189)	p-value
CR	2 (1.2)	3 (1.6)	-
PR	106 (61.3)	88 (46.6)	-
Stable disease	24 (13.9)	51 (27.0)	-
Progressive disease	4 (2.3)	18 (9.5)	-
Not evaluated	37 (21.4)	29 (15.3)	-
Objective response rate (CR+PR) (%)	62.4	48.2	0.006^a)

Adverse event	Irinotecan plus cisplatin (n=167)	Etoposide plus cisplatin (n=189)	p-value^a)
Anemia	45 (27.0)	33 (17.5)	0.035
Neutropenia	104 (62.3)	134 (71.0)	0.060
Thrombocytopenia	21 (12.6)	25 (13.2)	0.824
Neutropenic fever	31 (18.6)	33 (17.5)	0.823
Infection	34 (20.4)	33 (17.5)	0.515
Nausea	7 (4.2)	1 (0.5)	0.028
Vomiting	5 (3.0)	3 (1.6)	0.483
Diarrhea	17 (10.2)	5 (3.0)	0.003
AST elevation	2 (1.2)	8 (4.2)	0.110
ALT elevation	3 (1.8)	5 (2.6)	0.727

Treatment	Irinotecan plus cisplatin (n=173)	Etoposide plus cisplatin (n=189)
No systemic treatment	72 (41.6)	73 (38.6)
Etoposide containing regimen	84 (48.6)	9 (4.8)
Irinotecan containing regimen	10 (5.8)	65 (34.4)
Cyclophosphamide+doxorubicin+vincristine	30 (17.3)	26 (13.8)
Topotecan or belotecan	15 (8.7)	39 (20.6)
Paclitaxel	8 (4.6)	11 (5.8)
Ifosfamide	6 (3.5)	5 (2.6)
Others	12 (6.9)	11 (5.8)

	Present study	Noda et al. [11]	Lara et al. [12]	Hanna et al. [13]
Regimen	Irinotecan 65 mg/m² D 1,8	Irinotecan 60 mg/m² D 1,8,15	Irinotecan 60 mg/m² D 1,8,15	Irinotecan 65 mg/m² D 1,8
	Cisplatin 70 mg/m² D 1	Cisplatin 60 mg/m² D 1	Cisplatin 60 mg/m² D 1	Cisplatin 30 mg/m² D 1,8
	every 3 wk	every 4 wk	every 4 wk	every 3 wk
No. of patients	362	154	651	331
Median OS (mo)	10.9	12.8	9.9	9.3
Median PFS (mo)	6.5	6.9	5.8	4.1
Response rate (%)	62.4	65.0	60.0	48.0
Grade 3/4 neutropenia (%)	62.3	65.3	34.0	36.2
Grade 3/4 diarrhea (%)	10.2	16.0	19.0	21.3

Table 1. Baseline characteristics

Values are presented as number (%) unless otherwise indicated. ECOG PS, Eastern Cooperative Oncology Group performance status; RT, radiation therapy.

Wilcoxon rank sum test,

Chi-square test.

Table 2. Best overall response

Values are presented as number (%) unless otherwise indicated. CR, complete response; PR, partial response.

Chi-square test.

Table 3. Grade ≥ 3 adverse events in more than 2% of subjects

Values are presented as number (%).

Chi-square test.

Table 4. Systemic treatments after progression

Values are presented as number (%).

Table 5. Comparison of relevant studies of irinotecan-based chemotherapy in patients with ED SCLC

ED, extensive-disease; SCLC, small-cell lung cancer; D, day; OS, overall survival; PFS, progression-free survival.